Enovis Debuts AltiVate Reverse Glenoid System

Enovis Corporation today introduced the one-tray AltiVate Reverse Glenoid System, which expands the glenoid implant offering of the AltiVate Reverse to include modular, augmented baseplates.

Based on the company’s central screw fixation design with a minimum of 10 years of clinical follow-up,¹ the AltiVate Reverse Glenoid System received U.S. Food and Drug Administration (FDA) 510(k) clearance in May for use in reverse shoulder arthroplasty, including revisions.

“We are very pleased to offer a modular, augmented baseplate based on the proven central screw fixation principle of our legacy Reverse Shoulder Prosthesis (RSP) system²,” said Louie Vogt, group president of Enovis’ Reconstructive Business Group. “This addition to our AltiVate Reverse continues our long history of surgeon-driven innovation and commitment to exceptional patient outcomes.”

The AltiVate Reverse Glenoid System offers a modular baseplate with neutral and 15-inch wedge options, as well as multiple central compression screw lengths and diameters. The baseplate boss was designed to be more bone-sparing than any other currently available baseplate with a comparable central through-screw design to minimize the volume of bone removed and preserve the glenoid vault. It also adds four new glenospheres to the already robust RSP offering, giving surgeons a comprehensive selection to optimize the biomechanical needs of each individual patient and maximize implant longevity.^2,3 

Reverse shoulder arthroplasty represents over 60% of the more than 200,000 shoulder replacements performed annually in the United States.⁴ In a reverse shoulder replacement, the position of the ball and socket are switched. Developed in the 1980s in Europe and approved by the FDA in 2003, indications for this procedure continue to expand, increasing the demand for implants that can be used in a variety of patients.

The first surgery using AltiVate Reverse Glenoid was conducted by Mark Frankle, M.D., at Tampa General Hospital on July 8. Frankle is an international leader in shoulder surgery and has been performing reverse shoulder replacements for more than two decades.

“The new AltiVate Reverse Glenoid is a major innovation for my practice,” Frankle commented. “I now have one system with a variety of options to treat most, if not all, of my patients. It is simple and efficient while still offering the fixation and implant options I need, and it’s very exciting to be the first to use it clinically.”

Enovis Corporation is a medical technology company developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The company’s products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. Enovis’ shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV. 

References
^1,2 Cuff, et al. “Reverse shoulder arthroplasty for the treatment of rotator cuff deficiency: a concise follow-up, at a minimum of 10 years, of previous reports.” Journal of Bone and Joint Surgery. 2017.
³ Levin, et al. “Optimizing Muscle-Tendon Lengths in Reverse Total Shoulder Arthroplasty: Evaluation of Surgical and Implant-Design-Related Parameters.” Journal of Bone and Joint Surgery. 2024.
⁴ SmartTRAK®, https://app.smarttrak.com/markets/qs/32f3e3a89d794cbcac10027375315668

* Frankle is a paid consultant of Enovis.